EDIT Editas Medicine, Inc.

CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.

Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls

CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story.

Editas Medicine (NASDAQ:EDIT) outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for lowering LDL cholesterol. Speaking at the Cantor Healthcare Conference, President and Chief Executive

Editas Medicine (NASDAQ:EDIT) is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O’Neill said during a Wells Fargo discussion. O’Ne

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.

Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly loaded war chest.

Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.

Editas beats Q2 estimates as collaboration revenues surge, while EDIT-401 advanced toward clinical testing with encouraging preclinical data.

Editas (EDIT) delivered earnings and revenue surprises of +50.00% and +524.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Geron (GERN) delivered earnings and revenue surprises of -100.00% and +4.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?